On June 17th, the pharmaceutical network announced that the Kunming Pharmaceutical Group announced that “the current treatment of lupus erythematosus tablets is still in the stage of clinical phase II patients. The development of this new drug is a long-term work. Many uncertainties."
Kunming Pharmaceutical Group said on the 18th that the Phase II clinical trial is planned to be carried out in 15 hospitals and has been carried out in six hospitals including Peking Union Medical College Hospital.
Treatment of lupus erythematosus with dihydroartemisinin tablets has entered clinical phase II
In October 2015, due to the discovery that artemisinin can effectively reduce the mortality rate of malaria patients, Tu Yu became the first Chinese native scientist to win the Nobel Prize in science.
Kunming Pharmaceutical Group has been involved in the research and development and production of artemisinin antimalarials for more than 50 years. Since the development of the artemisinin project in the 1960s, Kunming has been responsible for the extraction and industrialization of artemisinin. Currently, Kunming medicine not only has a complete industrial chain business of artemisinin, the world's largest antimalarial drug substance manufacturer, the world's most complete variety of antimalarial drugs supplier. The artemisinin products currently sold mainly include: compound naphthoquine quinone tablets, artemether tablets, artemether raw materials, artemether injection, dihydroartemisinin piperaquine tablets.
September 2016, Kunming Pharmaceutical Group announced the signing of the China Academy of Traditional Chinese Medicine Research Institute "dihydroartemisinin tablets new indications - lupus Project Transfer Contract", to buy their holdings of China Academy of Traditional Chinese Medicine Institute of carcasses The patents and clinical approvals obtained by the pre-clinical research institute of the new indications for the development of dihydroartemisinin tablets - the lupus erythematosus research and development project.
As a partner, Kunming Pharmaceutical Group is responsible for the indication of systemic lupus erythematosus and systemic lupus erythematosus treated with dihydroartemisinin tablets submitted by the Institute of Chinese Medicine of China Academy of Chinese Medical Sciences, where the Tu Yu team is located. Clinical trials" conduct clinical trials.
According to Kunming Pharmaceutical Group, the project is undergoing Phase II clinical trials and is being tested in 15 hospitals. It has been carried out in six hospitals including Peking Union Medical College Hospital.
In addition, the Kunming Pharmaceutical Group announced on the evening of the 17th that the follow-up phase III clinical trial and the registration and approval procedures of the Food and Drug Administration are required. Only after the results of Phase II and Phase III clinical trials indicate the efficacy and safety of dihydroartemisinin tablets in the treatment of lupus erythematosus, the company can submit a new drug registration application to the Food and Drug Administration.
　　 "Dihydroartemisinin" Kunming Pharmaceutical Group, a leading innovative drugs more flowers
It is reported that Kunming Pharmaceutical Group was established in 1951 and listed on the Shanghai Stock Exchange in December 2000. As an established pharmaceutical company , Kunming Pharmaceutical Group has deep professional pharmaceutical experience and is a national key high-tech enterprise and one of the top 100 enterprises in China's pharmaceutical industry.
In recent years, in addition to continuing to enlarge and strengthen botanicals, traditional Chinese medicines and chemical medicines, Kunming Pharmaceutical Group has continuously increased capital investment and accelerated the development of completely innovative new medicines based on natural medicine through technological innovation. Developed 1 class of innovative drugs, such as Pycnogen and ARCO.
Since 2018, Kunming Pharmaceutical Group has adjusted the R&D resources and set up R&D institutions in Shanghai, Kunming and Beijing. Shanghai has set up three R&D platforms for small molecule innovative drugs, macromolecular biopharmaceuticals and high-end generic drugs to help enterprises accelerate their transformation. The Kunming R&D Center relies on the company's production base, and its functions focus on the pilot and industrialization of new product development and later. The secondary development of listed products; Beijing R&D Department relies on the concentration of government resources, mainly responsible for the declaration of drug development registration documents.
At the same time, it has also set up a scientific and technological innovation team for stroke treatment pharmacology research, Diabegone project innovation team, biological research and evaluation innovation team, drug structure transformation innovation team, new formulation research and innovation team, and Yunnan artemether series products research. Development and innovation team and other six innovative teams led by top experts at home and abroad.
In the key research and development projects of its layout, in addition to the dihydroartemisinin tablets for the treatment of lupus erythematosus into the clinical phase II trial, the biological product class 1 new drug long-acting hypoglycemic agent suparoride injection and natural medicine for stroke treatment 1 Clinical approvals were obtained for KPCXM18 injections of new drugs.
In addition, in order to further increase the secondary development of artemisinin products, Kunming Pharmaceutical Group has increased research and development of artemisinin derivatives artemether in leukemia, lung cancer, colorectal cancer, glioma, etc. Obtained nine invention patents such as “a pharmaceutical composition for treating lung cancerâ€.
At present, Kunming Pharmaceutical Group is focusing on technological innovations in the therapeutic fields of cardiovascular and cerebrovascular diseases, neurology and autoimmune diseases, and accelerates the transformation of the company into innovative enterprises.
Xi'an Healthway Biotech Co.,Ltd , https://www.xianhealthway.com